Search research articles
Contact Us
Filters
Showing results (11-20 of 14) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 14 results.
Reproductive Biomedicine Online
|
March 26, 2016
FMR1 gene CGG repeat variation within the normal range is not predictive of ovarian response in IVF cycles
Scott J Morin, Ashley W Tiegs, Jason M Franasiak, et al.
Biology of Reproduction
|
February 26, 2016
Next Generation Sequencing-Based Comprehensive Chromosome Screening in Mouse Polar Bodies, Oocytes, and Embryos
Nathan R Treff, Rebecca L Krisher, Xin Tao, et al.
RMD Open
|
May 21, 2026
Phase II randomised, placebo-controlled study to evaluate the efficacy and safety of an MK2 inhibitor in ankylosing spondylitis
Walter P Maksymowych, Anusha Yeshokumar, Elizabeth Cerullo, et al.
The Lancet. Rheumatology
|
May 4, 2026
Efficacy and safety of branebrutinib (BMS-986195), an irreversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2a, randomised, double-blind, placebo-controlled study
Mikkel Østergaard, Espen A Haavardsholm, Miroslawa Nowak, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 14) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 14 results.
Reproductive Biomedicine Online
|
March 26, 2016
FMR1 gene CGG repeat variation within the normal range is not predictive of ovarian response in IVF cycles
Scott J Morin, Ashley W Tiegs, Jason M Franasiak, et al.
Biology of Reproduction
|
February 26, 2016
Next Generation Sequencing-Based Comprehensive Chromosome Screening in Mouse Polar Bodies, Oocytes, and Embryos
Nathan R Treff, Rebecca L Krisher, Xin Tao, et al.
RMD Open
|
May 21, 2026
Phase II randomised, placebo-controlled study to evaluate the efficacy and safety of an MK2 inhibitor in ankylosing spondylitis
Walter P Maksymowych, Anusha Yeshokumar, Elizabeth Cerullo, et al.
The Lancet. Rheumatology
|
May 4, 2026
Efficacy and safety of branebrutinib (BMS-986195), an irreversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2a, randomised, double-blind, placebo-controlled study
Mikkel Østergaard, Espen A Haavardsholm, Miroslawa Nowak, et al.
Page
of 2